CANbridge Pharmaceuticals HK$685 million IPO
We advised CANbridge Pharmaceuticals on its IPO and HKEX listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Olympus $500 million senior notes offering
The debut offering consisted of 2.143% senior notes due 2026
Bilibili $1.6 billion sustainable convertible notes offering
The 0.5% convertible senior notes are due 2026
ANE HK$1.1 billion IPO
We advised ANE on its IPO and HKEX listing
Yili Group HK$6.25 billion acquisition of 34.33% of Ausnutria Dairy
We advised Yili on the acquisition of a controlling interest in Ausnutria
MicroTech Medical HK$1.82 billion IPO
We advised MicroTech Medical on its IPO and HKEX listing
Abbisko HK$1.7 billion IPO
We advised Abbisko on its IPO and HKEX listing
PHC Holdings ¥82.6 billion IPO
We advised the international managers in connection with the IPO and TSE listing
Hulic ¥97 billion common stock offering
We advised international joint lead managers on the global offering of common stock
Nippon Steel ¥300 billion convertible notes offering
We advised the joint lead managers and joint bookrunners on the unregistered convertible notes offering